Method for efficient gene coding of lysine acylated protein
Esterification improves the lipid solubility of acylated lysine, solving the problem of poor cell membrane permeability of non-natural amino acids, enabling the application of efficient gene codon expansion technology, and improving the screening of synthase mutants and the expression level of target proteins.
Patent Information
- Application Number
- CN202411064415.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
The low bioavailability of non-natural amino acids in cells leads to the failure of synthase mutant evolution and low expression levels of target proteins. This is mainly due to poor cell membrane permeability, especially the inability to effectively transport non-natural amino acids whose side chain structures deviate significantly from those of classical amino acids, and their unfavorable existence forms.
By improving the physicochemical properties of acylated lysine through esterification strategies to give it suitable lipid solubility and enhance cell membrane permeability, different esterified acylated lysine precursor compounds were designed and synthesized to enhance their cell permeability.
It improves the cell membrane permeability of non-natural amino acids, solves the problem of poor membrane permeability in the application of gene codon expansion technology, and enhances the screening of synthase mutants and the expression level of target proteins.
Smart Images

Figure CN118979060A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the fields of chemistry and biology, and in particular relates to a method for efficiently gene encoding lysine acylated protein. Background Art
[0002] The central law of life guides the metabolism of nucleic acids and proteins in biological macromolecules. Among them, protein post-translational modifications (PTMs) are important means for exercising and regulating protein biological functions, including classic modifications such as phosphorylation, methylation, ubiquitination, and acetylation. As PTMs research has gradually become a hot topic in proteomics, methods for site-specific introduction of modified amino acids and read-through expression have also been developed. Among them, the most representative gene codon expansion technology can meet the above needs. The development of gene codon expansion technology also stems from the extensibility of special codons in nature. For example, many species can encode a special amino acid, cysteine, through the stop codon UGA. The principle of gene codon expansion technology is based on the fact that the amber codon (UAG) in the stop codon of archaea can introduce special amino acids to maintain normal life activities. Inspired by this, researchers have constructed an independent and highly specific bio-orthogonal system: a uniquely recognized blank codon (UAG), tRNA that can recognize UAG, and aminoacyl-tRNA synthetase (aaRS) that can bind to tRNA and UAG. This system does not interact with endogenous aaRS / tRNA. This technology of selectively encoding unnatural amino acids into related proteins in mammalian cells through aminoacyl-tRNA synthetases that can specifically recognize unnatural amino acids and orthogonal tRNA has been increasingly widely used, but the low insertion efficiency and other issues that may exist currently limit its further application.
[0003] Researchers can generally improve the insertion efficiency of unnatural amino acids by optimizing the expression and activity of aminoacyl-tRNA synthetases and orthogonal tRNAs. However, the low bioavailability of unnatural amino acids in cells is often overlooked. In cell-based selection or screening systems, the strategy of protein insertion of unnatural amino acids often fails because unnatural amino acids cannot enter cells, making it impossible to evolve specific synthetase mutants. Alternatively, the low efficiency of unnatural amino acids entering cells results in low expression levels of target proteins into which unnatural amino acids are inserted, which fails to achieve the expected experimental results. These problems are attributed to the poor cell membrane permeability of unnatural amino acids. The poor cell membrane permeability of unnatural amino acids is based on two aspects. Unnatural amino acids with side chains similar to classical amino acids can be transported into cells through relatively nonspecific amino acid transporters, while unnatural amino acids with side chain structures that significantly deviate from classical amino acids may not be recognized by classical amino acid transporters and cannot be transported into cells through amino acid transporters. On the other hand, since the permeability of cell membranes to charged molecules is poorer than that to neutral molecules, unnatural amino acids, as amphiphilic compounds, only a small part exists in a neutral form under physiological pH conditions, which also makes it difficult for unnatural amino acids to pass through cell membranes and cannot form effective concentrations in cells, resulting in low expression levels of target proteins inserted with unnatural amino acids.
[0004] After searching, no reports on suitable esterification modification of the carboxyl group of non-natural amino acids were found. Summary of the invention
[0005] The present invention aims to solve the problems of failed evolution of synthetase mutants and low expression level of target protein inserted with non-natural amino acids due to low efficiency of acylated lysine entering cells. The esterification strategy is used to improve the physical and chemical properties of acylated lysine so that it has suitable lipid solubility. Most of the compound molecules exist in a neutral form, which greatly improves the cell membrane permeability and solves the problem of application of gene codon expansion technology caused by poor membrane permeability.
[0006] The technical solution of the present invention is as follows:
[0007] In a first aspect, the present invention provides a method for efficiently genetically encoding lysine acylated proteins, comprising the following steps:
[0008] Step 1: In view of the high polarity and poor cell membrane permeability of acylated lysine itself, different esterified acylated lysine precursor compounds are designed and synthesized to increase lipid solubility and improve cell permeability;
[0009] Step 2: Evaluate the cytotoxicity, cell entry rate and hydrolysis rate of the different esterified acylated lysine precursor compounds obtained in step 1;
[0010] Step 3: Based on the gene codon expansion technology, the expression level of the site-specific acylation target protein of the esterified acylated lysine group was evaluated and verified.
[0011] In the second aspect, the present invention protects the esterified acylated lysine represented by formula I or its pharmaceutically acceptable salt, solvate, racemate and isomer:
[0012]
[0013] In Formula I:
[0014] R1 is selected from C1-C3 alkyl, C1-C3 alkanoylmethylene, or C6-C10 aryl;
[0015] R2 is selected from unsubstituted or substituted C1-C6 straight or branched chain alkanoyl, benzoyl.
[0016] In a specific embodiment,
[0017] R1 is methyl, ethyl, acetoxymethylene, phenyl, or benzyl;
[0018] R2 is formyl, acetyl, 2-hydroxypropionyl, propionyl, isobutyryl, (E)2-butenoyl, benzoyl, malonyl, succinic acid monoyl, 3-hydroxybutyryl, 3-hydroxy-3-methylglutaryl, 2-hydroxy-3-monophosphate propionyl, 2-hydroxyacetyl, 2-oxoacetyl, 2,3-dihydroxypropionyl, 2-oxopropionyl, oxalyl.
[0019] In a more specific embodiment, the esterified acylated lysine is selected from any one of the following:
[0020]
[0021] Esterification modification of acylated lysine can improve its efficiency in entering cells, which has positive significance for the screening of synthetase mutants and the improvement of the expression level of target proteins by inserting non-natural amino acids.
[0022] In a third aspect, the present invention also protects the use of any of the above-mentioned esterified acylated lysine or its pharmaceutically acceptable salts, solvates, racemates and isomers in the preparation of recombinant proteins.
[0023] In a fourth aspect, the present invention also protects a recombinant protein, wherein the amino acid at at least one position in the amino acid sequence of the wild-type protein of the recombinant protein is mutated to any of the esterified acylated lysines described above.
[0024] In a specific embodiment, the wild-type protein includes a functional protein having a therapeutic or preventive effect on a disease, a diagnostic protein, an industrial enzyme, or an antibody or an antibody fragment thereof having a therapeutic and / or preventive effect on a disease.
[0025] In a specific embodiment, any of the above-mentioned esterified acylated lysine is site-specifically introduced into the wild-type protein using gene codon expansion technology.
[0026] In a specific embodiment, the wild-type protein is selected from α-Ι antitrypsin, angiostatin, antihemolytic factor, antibody, apolipoprotein, apoprotein, atrial natriuretic factor, atrial natriuretic polypeptide, atrial peptide, CXC chemokine, T39765, NAP-2, ENA-78, gro-a, gro-b, gro-c, IP-10, GCP-2, NAP-4, SDF-1, PF4, MIG, calcitonin, C-kit ligand, cytokine, CC chemokine, monocyte chemoattractant protein-1, monocyte chemoattractant protein 2, monocyte chemoattractant protein-3, monocyte monocyte inflammatory protein-1α, monocyte inflammatory protein-1β, RNATES, I309, R83915, R91733, HCC1, T58847, D31065, T64262, CD40, CD40 ligand, collagen, colony stimulating factor, complement factor 5a, complement inhibitor, complement receptor 1, cytokine, epithelial neutrophil activation peptide-78, MIP-16, MIP-1, epidermal growth factor, epithelial neutrophil activation peptide, erythropoietin, exfoliating toxin, factor IX, factor VII, factor VIII, factor X, fibroblast Cell growth factor, fibrinogen, fibronectin, four-helix bundle protein, G-CSF, glp-1, GM-CSF, glucocerebrosidase, gonadotropin, growth factor, growth factor receptor, hedgehog protein, hemoglobin, hepatocyte growth factor, hirudin, human growth hormone, human serum albumin, ICAM-1, ICAM-1 receptor, LFA-ULFA-1 receptor, insulin, insulin-like growth factor, IGFI, IGF-II, interferon, IFN-α, IFN-0.IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5 , IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, keratinocyte growth factor, lactoferrin, leukemia inhibitory factor, luciferase, nerve growth factor, neutrophil inhibitory factor, oncostatin M, osteogenic protein, oncogene products, paracitonin, parathyroid hormone, PD-ECSF, PDGF, peptide hormones, pleiotrophin, protein A, protein G, pth, pyrogenic exotoxin A, pyrogenic exotoxin B and pyrogenic exotoxin C, pyy, relaxin, renin, SCF, soluble complement receptor I, soluble I-CAM 1, soluble interleukin receptor, soluble TNF receptor, somatomedin, somatostatin, growth hormone, streptokinase, superantigen, staphylococcal enterotoxin, SEA.SEB, SECT, SEC2, SEC3, SED, SEE, steroid hormone receptor, superoxide dismutase, toxic shock syndrome toxin, thymosin α1, tissue plasminogen activator, tumor growth factor, tumor necrosis factor, tumor necrosis factor α, tumor necrosis factor β, tumor necrosis factor receptor, VLA-4 protein, VCAM-1 protein, vascular endothelial growth factor, urokinase, mos, ras, raf, met, p53, tat, fos, myc, jun, myb, rel, estrogen receptor, progesterone receptor, testosterone receptor, aldosterone receptor, LDL receptor, corticosterone, fructose bisphosphate aldolase, etc.
[0027] In specific embodiments, the antibody or antibody fragment thereof includes a whole antibody, scFv, Fab, Fab', F(ab')2, scFv_Fc, Triabody, Diabody, Minibody, Nanobody, DARPins or affibody, etc.
[0028] Beneficial Effects
[0029] The esterified acylated lysine provided by the present invention improves the physical and chemical properties of acylated lysine through an esterification strategy, making it have suitable lipid solubility, greatly improving the cell membrane permeability of the compound molecule, and solving the problem existing in the application of gene codon expansion technology caused by poor membrane permeability. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 Non-natural amino acid esterification strategy based on gene codon expansion technology improves site-specific acylation protein expression.
[0031] Figure 2 Characterization, cytotoxicity evaluation and time-course kinetics of lactylated lysine and its derivatives; wherein, (A) the structural formulas of Klac, Klac-OMe and Klac-OEt; (B) the chromatograms of lactylated lysine and its esterified derivatives; (C) the cytotoxicity evaluation of lactylated lysine and its derivatives; (D) the time-course kinetics of Klac, KlacOMe and KlacOEt entering cells at a concentration of 0.1 mM; (E) the AUC ratio of Klac, KlacOMe and KlacOEt entering cells at a concentration of 0.1 mM.
[0032] Figure 3Expression of site-specific lactylated proteins in mammalian cells based on esterified Klac; (A) inverted fluorescence imaging of co-transfected pcDNA-mCherry-TAG-EGFP / pNEU-Mm-KlacRS plasmid in HEK293T cells treated with lactylated lysine and its esterified derivatives; (B) relative fluorescence ratio (green fluorescence / red fluorescence); (C) immunoblot analysis of site-specific lactylated modified protein expression in HEK293T cells.
[0033] Figure 4 Site-specific lactylated protein expression in the E. coli system; (A) Fluorescence imaging of the lactylated EGFP protein suspension; (B) Relative fluorescence level of the lactylated EGFP protein suspension.
[0034] Figure 5 Immunoblotting analysis of site-specific introduction of esterified Klac into pBad-EGFP (Y39TAG) in the E. coli system.
[0035] Figure 6 Immunoblotting analysis of site-specific introduction of ALDOA by esterified Klac in the E. coli system; (A) Esterified Klac in the E. coli system induced the expression of ALDOA-147Klac, and the purified protein was stained with Coomassie Brilliant Blue; (B) Esterified Klac in the E. coli system induced the expression of purified ALDOA-147Klac protein, which could be correctly recognized by the ALDOA / L-Lactylation antibody.
[0036] Figure 7 The lactylated peptide DGADFAK in ALDOA-147Klac lac MS / MS spectrum of WR. DETAILED DESCRIPTION
[0037] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0038] The specific implementation of the present invention is described in detail below in conjunction with specific embodiments.
[0039] Example 1: Preparation of lactylated lysine Klac and esterified Klac
[0040]
[0041] Reagents and conditions: (i) 1 (10.0 mmol), methanol (50 mL), dichlorothionyl (10.0 eq.), 0°C, 0.5 h, room temperature, 10 h, 95% (2); (ii) 2 (9.0 mmol), L-lactic acid (1.2 eq.), N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (1.5 eq.), N,N-diisopropylethylamine (4.0 eq.), anhydrous N,N-dimethylformamide, room temperature, 10 h, 80% (3); (iii) 3 (7.0 mmol), hydrogen, palladium / carbon (mass fraction 10%), methanol (30 mL), room temperature, 8 h, 60% KlacOMe; (iv) KlacOMe or KlacOEt (2.0 mmol), tetrahydrofuran (50 mL), 0°C, aqueous lithium hydroxide solution (2.5 eq) was added dropwise, 0°C, 15 h, 78% Klac; (v) 1 (10.0 mmol), ethanol (50 mL), dichlorothionyl (10.0 eq.), 0°C, 0.5 h, room temperature, 16 h, 90% (4); (vi) 5 (7.0 mmol), hydrogen, palladium / carbon (mass fraction of 10%), methanol (30 mL), reflux, 12 h, 70% KlacOEt.
[0042] Example 2 Preparation of (S)-5-(((Benzyloxy)carbonyl)amino)-6-methoxy-6-oxohexanoic acid-1-amino hydrochloride (2)
[0043]
[0044] Compound 1 (2.803 g, 10.0 mmol, 1.0 eq.) and methanol (50 mL) were added to a 250 mL dry single-mouth round-bottom flask, and the mixed solution was stirred at 0 ° C for 15 minutes. Thionyl chloride (7.26 mL, 100.0 mol, 10 eq.) was added dropwise under stirring. After the addition was complete, the reaction flask was moved to room temperature and stirred for 10 hours. The reaction was monitored by LC-MS and TLC. After the reaction was completed, the excess thionyl chloride and methanol were dried by spin drying, anhydrous ether (80 mL) was added, and the mixture was stirred at room temperature for 12 hours. A white solid precipitated, filtered, and the filter cake was washed with ice ether (20 mL × 2) to obtain a white solid compound 2 (3.140 g, 95%) for standby use. 1H NMR (500MHz, DMSO-d6) δ7.75-7.63(m,4H),7.40-7.28(m,5H),5.75(s,2H),5.04(d,J=2.9Hz,2H),4.04(d,J=4.3H z,1H),3.64(s,3H),2.76(d,J=6.7Hz,2H),1.74-1.58(m,2H),1.52(q,J=7.4Hz,2H),1.36(dt,J=15.6,8.6Hz,2H). 13 C NMR (126MHz, DMSO-d6) δ172.76,156.11,136.84,128.33,127.84,127.74,65. 53,54.87,53.66,51.84,39.94,38.54,30.10,26.43,22.33.MS: [M+1]295.16.
[0045] Example 3 Methyl-N 2 -((Benzyloxy)carbonyl)-N 6 Preparation of -((S)-2-hydroxypropionyl-L-lysine (3)
[0046]
[0047] Compound 2 (2.977 g, 9.0 mmol, 1.0 eq.) obtained in the previous step, L-lactic acid (972.8 mg, 10.8 mmol, 1.2 eq.), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (5.133 g, 13.5 mmol, 1.5 eq.), N,N-diisopropylethylamine (6.27 mL, 36.0 mmol, 4.0 eq.) and N,N-dimethylformamide (25 mL) were added to a 100 mL dry single-mouth round-bottom flask. The reaction mixture was stirred at room temperature for 10 hours, and the reaction was monitored by LC-MS and TLC. After the reaction, water (60 mL) was added to the reaction solution, and ethyl acetate (3×60 mL) was added for extraction, washed with saturated sodium carbonate, washed with saturated brine, dried over anhydrous sodium sulfate, spin-dried, and subjected to column chromatography to obtain compound 3 (2.638 g, 90%). 1H NMR (500MHz, DMSO-d6) δ7.68(d,J=7.7Hz,1H),7.65(s,1H),7.45-7.26(m,5H),5.39(d,J=5.0Hz,1H),5.03(s,2H),3.99(td,J=8.6,5.1Hz, 1H),3.96-3.88(m,1H),3.63(s,3H),3.04(d,J=6.5Hz,2H),1.72-1.55(m,2H),1.43-1.35(m,2H),1.33-1.23(m,3H),1.19(d,J=6.7Hz,3H). 13 C NMR(126MHz,DMSO-d6)δ174.83,173.43,156.63,137.42,128.85,128.33,128.23,127.69 ,67.77,66.01,54.39,52.29,38.23,30.87,29.51,29.21,23.27,21.63.MS:[M+1]367.18.
[0048] Example 4 Methyl-N 6 Preparation of -((S)-2-hydroxypropionyl)-L-lysine (KlacOMe)
[0049]
[0050] Compound 3 (2.564 g, 7.0 mmol, 1.0 eq.), methanol (30 mL) and palladium carbon (256 mg) obtained in the previous step were added to a 100 mL dry single-mouth round-bottom flask. The hydrogen in the reaction system was replaced three times using a balloon filled with hydrogen. The reaction mixture was stirred at room temperature for 8 hours, and the reaction was monitored by LC-MS and TLC. After the reaction was completed, palladium carbon was removed by diatomaceous earth filtration, the filtrate was concentrated, and the compound KlacOMe (1.128 g, 60%) was obtained by column chromatography. 1 H NMR (500MHz, DMSO-d6) δ8.45(s,3H),7.66(s,1H),6.22(s,1H),4.00(d,J=6.4Hz,1H),3.94(d,J=6.8Hz,1H),3.74(s,3H),3.05(d ,J=6.6Hz,2H),1.82-1.72(m,2H),1.41(q,J=6.7,6.2Hz,2H),1.35(d,J=7.9Hz,1H),1.26(d,J=8.2Hz,1H),1.19(d,J=6.7Hz,3H). 13C NMR (126MHz, DMSO-d6) δ174.47,170.03,67.30,52.76,51.95,37.64,29.76,28.66,21.60,21.16.MS: [M+1]233.15.
[0051] Example 5 N 6 Preparation of -((S)-2-hydroxypropionyl)-L-lysine (Klac)
[0052]
[0053] Add compound KlacOMe or KlacOEt (2.0 mmol, 1.0 eq.) and tetrahydrofuran (50 mL) to a 100 mL dry single-mouth round-bottom flask. Stir the reaction solution at 0°C for 10 minutes, and use a dropping funnel to drop lithium hydroxide solution (119.7 mg, 5.0 mol, 2.5 eq., in 100 mL H2O). After the addition is complete, stir the reaction at 0°C for 15 hours, and monitor the reaction by LC-MS and TLC. After the reaction, the pH was adjusted to 4-5 with 1M hydrochloric acid, and the excess tetrahydrofuran and water were dried by spin drying. The crude product was separated by preparative liquid phase to obtain compound Klac (340.5 mg, 78%). 1H NMR (500MHz, Deuterium Oxide) δ4.21 (q, J = 6.9 Hz, 1H), 3.76 (t, J = 6.2 Hz, 1H), 3.22 (t, J = 6.9 Hz, 2H), 1.86 (tt, J = 12.6, 6.1 Hz, 2H), 1.56 (p, J = 7.3 Hz, 2H), 1.40 (ddt, J = 20.7, 10.2, 3.6 Hz, 2H), 1.33 (d, J = 6.9 Hz, 3H). 13C NMR (126MHz, Deuterium Oxide)δ177.44,174.27,67.66,54.32,38.46,29.92,28.05,21.62,19.65.MS: [M+1]219.13.
[0054] Example 6 Preparation of (S)-5-(((Benzyloxy)carbonyl)amino)-6-ethoxy-6-oxohexanoic acid-1-amino hydrochloride (4)
[0055]
[0056] Compound 1 (2.803 g, 10.0 mmol, 1.0 eq.) and ethanol (50 mL) were added to a 250 mL dry single-mouth round-bottom flask, and the mixed solution was stirred at 0 ° C for 15 minutes. Thionyl chloride (7.26 mL, 100.0 mol, 10 eq.) was added dropwise under stirring. After the addition was complete, the reaction flask was moved to room temperature and stirred for 10 hours. The reaction was monitored by LC-MS and TLC. After the reaction was completed, the excess thionyl chloride and ethanol were dried by spin drying, anhydrous ether (80 mL) was added, and the mixture was stirred at room temperature for 12 hours. A white solid precipitated, filtered, and the filter cake was washed with ice ether (20 mL × 2) to obtain a white solid compound 2 (3.140 g, 95%) for standby use. 1 H NMR(500MHz,DMSO-d6)δ7.84(s,3H),7.69(d,J=7.7Hz,1H),7.42-7.24(m,5H),5.04(d,J=8.5Hz,2H),4.09(dq,J=7.4,3.4Hz,2H),4 .05-3.93(m,1H),2.76(d,J=6.8Hz,2H),1.72-1.57(m,2H),1.54(q,J=7.4Hz,2H),1.37(q,J=8.4,7.6Hz,2H),1.17(t,J=7.1Hz,3H). 13 C NMR(126MHz,DMSO-d6)δ172.31,156.18,136.96,128.36,127.86,127.75,117.69, 115.34,65.52,60.50,53.84,38.55,30.13,26.49,22.41,14.04.MS:[M+1]309.18.
[0057] Example 7 Ethyl-N 2 -((Benzyloxy)carbonyl)-N 6 Preparation of -((S)-2-hydroxypropionyl)-L-lysine (5)
[0058]
[0059] Compound 4 (2.977 g, 9.0 mmol, 1.0 eq.), L-lactic acid (972.8 mg, 10.8 mmol, 1.2 eq.), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (5.133 g, 13.5 mmol, 1.5 eq.), N,N-diisopropylethylamine (6.27 mL, 36.0 mmol, 4.0 eq.) and N,N-dimethylformamide (25 mL) were added to a 100 mL dry single-mouth round-bottom flask. The reaction mixture was stirred at room temperature for 10 hours, and the reaction was monitored by LC-MS and TLC. After the reaction, water (60 mL) was added to the reaction solution, and ethyl acetate (3×60 mL) was added for extraction, washed with saturated sodium carbonate, washed with saturated brine, dried over anhydrous sodium sulfate, and subjected to column chromatography to obtain compound 5 (2.638 g, 90%). 1 H NMR(500MHz,DMSO-d6)δ7.66(d,J=8.0Hz,2H),7.40-7.26(m,5H),5.39(d,J=4.9Hz,1H),5.09-4.95(m,2H),4.13-4.03(m,2H),3.99 -3.89(m,2H),3.04(q,J=6.7Hz,2H),1.71-1.55(m,2H),1.40(q,J=7.0Hz,2H),1.33-1.26(m,2H),1.18(dd,J=11.3,6.9Hz,6H).13C NMR (126MHz, DMSO-d6) δ174.82,172.92,156.63,137.47,128.83,128.31,128.21,67. 77,65.96,60.90,54.49,38.25,30.87,29.23,23.29,21.63,14.56.MS: [M+1]381.20.
[0060] Example 8 Preparation of Ethyl-N6-((S)-2-Hydroxypropionyl)-L-Lysine (KlacOEt)
[0061]
[0062] Compound 5 (2.564 g, 7.0 mmol, 1.0 eq.), methanol (30 mL) and palladium carbon (256 mg) obtained in the previous step were added to a 100 mL dry single-mouth round-bottom flask. The hydrogen in the reaction system was replaced three times using a balloon filled with hydrogen. The reaction mixture was stirred at room temperature for 8 hours, and the reaction was monitored by LC-MS and TLC. After the reaction was completed, palladium carbon was removed by diatomaceous earth filtration, the filtrate was concentrated, and the compound Klac-OMe (1.128 g, 60%) was obtained by column chromatography.1 H NMR (500MHz, DMSO-d6) δ8.34(s,2H),7.65(s,1H),4.27-4.14(m,2H),4.00(s,1H),3.93(q,J=6.7Hz,1H),3.06(q,J=6.6Hz,2 H),1.76(dt,J=11.0,5.8Hz,2H),1.42(q,J=6.6,6.1Hz,2H),1.43-1.31(m,2H),1.24(t,J=7.1Hz,3H),1.19(d,J=6.7Hz,3H). 13 C NMR (126MHz, DMSO-d6) δ174.33,169.53,67.24,61.79,51.89,37.60,29.74,28.63,21.54,21.13,13.92.MS: [M+1]247.16.
[0063] The chemical structures of lactylated lysine Klac and esterified Klac are as follows Figure 2 -A, and its chromatographic retention time is as follows Figure 2 -B. The specific chromatographic method is: using LC / Q-TOF (Agilent Technologies, Inc., 6546) for analysis, mobile phase A is 0.1% formic acid water, mobile phase B is acetonitrile, the flow rate is 0.3 mL / min, the chromatographic column is ACQUITY UPLC HSS T3 chromatographic column (2.1×100 mm, Waters), and the chromatographic gradient is as follows: 0.0-3.0 min, 5% B; 3.0-10.0 min, 65% B; 10.0-12.0 min, 95% B; 12.0-12.5 min, 95% B; 12.5-13.0 min, 5% B; 13.0-17.0 min, 5% B.
[0064] Evaluation of cytotoxicity of lactylated lysine Klac and esterified Klac. HEK293T cells were seeded in 96-well plates, with 8 e per well. 3 -1e 4100 μL sterile PBS solution was added to the outermost circle of the 96-well plate to block the edge effect and delay the consumption of the central cell culture medium. The plate was pre-cultured in a 37°C incubator for about 24 hours to allow the cells to adhere to the wall. DMEM culture medium (containing 10% FBS) was used to prepare solutions containing final concentrations of 0.1 mM Klac, 0.1 mM KlacOMe, 0.1 mM KlacOEt, 0.2 mM Klac, 0.2 mM KlacOMe, and 0.2 mM KlacOEt, and the cells were cultured for 24 hours by replacing the drug-containing culture medium. After the end, the CCK-8 reagent was diluted with phenol red-free DMEM culture medium under light-proof conditions to a final concentration of 10% (CCK-8: phenol red-free culture medium = 1:9), the culture medium in the plate was discarded, and the residual culture medium was washed away with 100 μL PBS, and repeated twice. 100 μL of the prepared 10% was added to each well. CCK-8 reagent was incubated at 37°C. When the control group turned golden yellow, the ELISA reader was used to read the values. The expected OD value of the control group was 0.8-1.2. The absorbance was detected at a wavelength of 450nm, and then the data was analyzed. Figure 2 As shown in Figure 5-C, the activity of HEK293T cells treated with three types of UAA, and no obvious cytotoxicity was observed at UAA below 0.25 mM.
[0065] Kinetics of cellular uptake of esterified Klac: Determine the rate of esterified Klac entering cells. HEK 293T cells in logarithmic growth phase were taken at 3.5e 5 / well density was plated in a 12-well plate 24h in advance, with 1mL DMEM+10% FBS complete medium in each well, and cultured at 37°C and 5% CO2. 1mL DMEM+10% FBS complete medium containing 0.1mM Klac, KlacOMe, and KlacOEt was given at 0.5, 2, 4, 8, 12, and 24h time points. At the last time point, the cell culture medium was discarded and then rinsed three times with PBS. 500μL of pre-cooled metabolite extractant (acetonitrile: water = 80:20, containing 0.5μg / mL DL-4-chlorophenylalanine) was added to each well, and the extract was collected in a 1.5mL ep tube. After centrifugation at 18000rpm*10min*4℃, 450μL of vacuum concentration was transferred. The sample was re-dissolved with 40μL 0.1% FA water, and the supernatant was taken for LC-MS / MS after 18000rpm*10min*4℃*two centrifugations. The experimental results showed that the esterified form of Klac can enter cells faster than Klac and be metabolized to Klac( Figure 2 -D, E).
[0066] Validation of site-directed introduction of esterified Klac in HEK293T cells. HEK 293T cells in logarithmic growth phase were taken at 3e 5 / well density in a 6-well plate 24h in advance, 1mL DMEM+10% FBS complete medium in each well, culture at 37℃ and 5% CO2. Replace half of the complete medium and incubate at 37℃ for half an hour. Use serum-free DMEM medium to prepare the mCherry-TAG-EGFP transfection system, 1.50μg plasmid (0.75μg pCMV-mCherry-TAG-EGFP, 0.75μg pNEU-Mm-KlacRS) and 4.5μL polyjet in each well. The transfection system is allowed to stand at room temperature for 15min to promote the binding of plasmid and polyjet, and the corresponding wells are dotted according to the experimental design. After 12h of transfection, replace 2mL of DMEM+10% FBS medium containing 0.10mM or 0.25mM Klac, KlacOMe, KlacOEt in each well and continue to culture for 48h, then observe under an inverted fluorescence microscope. Figure 3 -A,B.
[0067] After observation, discard the cell culture medium, wash the residual culture medium 3 times with 1mL PBS, collect the cells in a 1.5mL ep tube with a cell scraper, and obtain the cell pellet at 1000g*10min*4℃. Add 100μL RIPA lysis buffer (containing 1% protease inhibitor) to each tube of cells, blow off the cell pellet and lyse on ice for 30min, then use an ultrasonic cell disruptor to fully lyse the cells, ultrasonicate on ice for 3s and stop for 5s (energy 20%) for a total of 30s. Centrifuge at 14000rpm*10min*4℃ to obtain the supernatant, incubate at 37℃ for 30min using the BCA protein quantification method, and use an enzyme-linked immunosorbent assay to measure the absorbance at 562nm to calculate the protein concentration. Add loading buffer to the supernatant and heat in boiling water for 8min, then ice bath for 5min. Load on 10% SDS-PAGE gel, separate at 150V for 60min, cut the corresponding position of the protein under the marker indication, and transfer to a PVDF membrane. Use 5% milk prepared in TBST for dynamic blocking at room temperature for 1 hour, then use TBST to remove residual milk and shake for 5 minutes*3 times. Incubate the primary antibody (anti-L-Lactylation, anti-mCherry, anti-GFP, anti-β-actin) overnight, wash the membrane with TBST at room temperature for 5 minutes*3 times, add 10000× rabbit / mouse secondary antibody (5% BSA, prepared in TBST) and incubate at 37℃ for 1 hour, wash the membrane with TBST at room temperature for 5 minutes*5 times, and add ECL luminescent liquid for exposure in a dark room. The results of immunoblotting experiments show that the esterified form of KLac can achieve better full-length expression of the target protein of the gene codon expansion technology, and the obvious introduction of lactylation post-translational modification is significantly stronger than the prototype Klac, see Figure 3 -C.
[0068] Verification of site-directed introduction of esterified Klac in E.coli system. To verify the application of esterified Klac in E.coli system, the tyrosine (Y) at position 39 of pBad-EGFP was mutated to an amber stop codon (TAG) and combined with gene codon expansion technology to achieve site-directed introduction of lactylation modification. First, construct DH10B competent cells with pBad-EGFP single transformation: take DH10B competent cells on ice and add 1μL of pBad-EGFP (Y39TAG) plasmid and let it stand for 30min, then place it in a 42℃ water bath for heat shock for 90s and ice bath for 5min, add 700μL of anti-LB medium, incubate at 37℃ for 1h, take an appropriate amount of bacterial solution and plate it on Amp-resistant solid LB plate, and culture it at 37℃ overnight. The next day, pick monoclonal bacteria in the clean bench and culture them in Amp-resistant medium at 220rpm*12h*37℃. The bacterial solution was centrifuged at 4000rpm*5min*4℃ to obtain bacterial precipitate, and the bacterial precipitate was resuspended with CCMB 80 buffer, and centrifuged again at 4000rpm*5min*4℃ to obtain bacterial precipitate, and the precipitate was resuspended with CCMB 80 buffer and dispensed into multiple 1.5mL ep tubes, and liquid nitrogen was used to quickly freeze to obtain pBad-EGFP(Y39TAG) single transformation competent cells. The pEvol-KlacRS plasmid was transformed into pBad-EGFP(Y39TAG)-DH10B competent cells, and the bacterial solution was applied to CM / Amp-double antibody solid plate. After overnight culture at 37℃, the monoclonal bacterial cells were picked up the next day and placed in CM / Amp-double antibody culture medium, and the OD 600 value was shaken to 0.4-0.8, and the fluorescence emission at 510nm was measured by enzyme-linked immunosorbent assay at 480nm excitation wavelength ( Figure 4 ) and collect the bacteria for WB verification ( Figure 5 ). The experimental results show that esterified Klac is also applicable in the E. coli system and exhibits stable and efficient site-specific introduction efficiency, providing the possibility for subsequent bacterial engineering to express large amounts of purified proteins modified with lactylation at specific sites.
[0069] After the site-specific introduction of esterified Klac, we set out to verify the purified expression of the target protein modified by site-specific lactylation. By optimizing the esterified Klac, we increased the upper limit of the application of gene codon expansion technology in bacterial engineering and expressed more site-specific lactylated modified proteins at one time. Taking fructose-bisphosphate aldolase A (ALDOA) as an example, the study showed that there was a high-degree lactylation modification at its K147 site, which was closely related to its functional regulation and had very important research significance. Therefore, 1 mL of the plasmid pBad-ALDOA (K147) / pEvol-KlacRS co-transfection solution was added to 100 mL CM / Amp-double-antibody medium, and arabinose with a final concentration of 0.2% was added to induce overnight at 220 rpm*16h*30°C. The next day, the bacteria were centrifuged at 4000 rpm*30 min*4°C to obtain the bacteria. 1 g of wet bacteria was added to 20 mL of lysis buffer (250 mM NaCl, 50 mM Tris, 5 mM imidazole, containing 1% PrI), and lysozyme with a final concentration of 1.0 mg / mL was added to lyse the bacteria at 37°C for 10 min, and then the bacterial cell wall was broken using a cell sonicator. The bacterial lysate was transferred to a 1.5 mL ep tube and centrifuged at 18000 rpm*30 min*4°C to obtain the supernatant. The ALDOA (K147) purified protein was eluted through a commercial nickel column, and the purified protein was concentrated by centrifugation using a protein ultrafiltration column. The immunoblotting experiment verified that the use of esterified Klac in the E. coli system can also achieve site-specific introduction of lactylation modification with high single-time yield. Figure 6 .
[0070] To confirm that esterified Klac can be introduced into the ALDOA-K147 site in the gene codon expansion technology, and that only this site undergoes lactylation modification, we further used nanoLC-MS / MS for proteomics analysis. Take 100 μg of ALDOA-147Klac purified protein, add 100 μL 8M urea to denature the protein at room temperature for 30 minutes, add dithiothreitol with a final concentration of 10 mM to react at 56°C for 30 minutes to open the disulfide bonds in the protein, add iodoacetamide with a final concentration of 50 mM to react at room temperature in the dark for 30 minutes to bind to free sulfhydryl groups to prevent the occurrence of disulfide bonds again, add an equal volume of dithiothreitol to terminate the reductive alkylation reaction, and add 1 μg Trypsin to digest overnight at 37°C. After the peptide solution was evaporated, it was re-dissolved in 0.1% FA H2O, desalted using a commercial ziptip-C18 column, and injected into nanoLC-MS / MS. The experimental results showed that esterified Klac can achieve site-specific introduction of lactylation modification in the E. coli system, has good bioorthogonality, and the probability of mismatching and misinsertion is extremely low. Figure 7 .
[0071] Proteomic analysis confirmed that the ALDOA mutant induced by esterification Klac had and only had the target site K147 undergoing lactylation modification. The mass spectrometry detection signal matched well and had the characteristic cyclic imine ion of lactylation modification, indicating that the result was true and reliable.
[0072] The above are only several exemplary embodiments of the present invention, and do not limit the present invention in any form. Although the present invention is disclosed as above with preferred embodiments, it is not intended to limit the present invention. Any technician familiar with the profession, without departing from the scope of the technical solution of the present invention, using the above disclosed technical content to make some changes or modifications are equivalent to equivalent implementation cases, and all belong to the scope of the technical solution of the present invention.
Claims
1. A method for efficiently genetically encoding lysine acylated proteins, characterized in that: The method comprises the following steps: Step 1: Design and synthesize different esterified acylated lysine precursor compounds; Step 2: evaluating the cytotoxicity, cell entry rate and hydrolysis rate of the esterified acylated lysine precursor compound obtained in step 1; Step 3: Based on the gene codon expansion technology, the expression level of the site-specific acylation target protein of the esterified acylated lysine group was evaluated and verified.
2. The compound represented by formula I or its pharmaceutically acceptable salt, solvate, racemate and isomer: In Formula I: R1 is selected from C1-C3 alkyl, C1-C3 alkanoylmethylene, or C6-C10 aryl; R2 is selected from unsubstituted or substituted C1-C6 straight or branched chain alkanoyl, benzoyl.
3. The compound according to claim 2 or its pharmaceutically acceptable salt, solvate, racemate and isomer, characterized in that: R1 is methyl, ethyl, acetoxymethylene, phenyl, or benzyl; R2 is formyl, acetyl, 2-hydroxypropionyl, propionyl, isobutyryl, (E)2-butenoyl, benzoyl, malonyl, succinic acid monoyl, 3-hydroxybutyryl, 3-hydroxy-3-methylglutaryl, 2-hydroxy-3-monophosphate propionyl, 2-hydroxyacetyl, 2-oxoacetyl, 2,3-dihydroxypropionyl, 2-oxopropionyl, oxalyl.
4. A compound as described in any one of the following or a pharmaceutically acceptable salt, solvate, racemate and isomer thereof:
5. Use of the compound according to any one of claims 2 to 4 or its pharmaceutically acceptable salt, solvate, racemate and isomer in the preparation of recombinant protein.
6. A recombinant protein, characterized in that The amino acid mutation at at least one position in the amino acid sequence of the wild-type protein is the compound in claims 2-4.
7. The recombinant protein according to claim 6, characterized in that The wild-type protein includes a functional protein having a therapeutic or preventive effect on a disease, a diagnostic protein, an industrial enzyme, or an antibody or an antibody fragment thereof having a therapeutic and / or preventive effect on a disease.
8. The recombinant protein according to claim 6, characterized in that The compound described in any one of claims 2-4 is site-specifically introduced into the wild-type protein using gene codon expansion technology.
9. The recombinant protein according to claim 7, characterized in that The wild-type protein is selected from α-Ι antitrypsin, angiostatin, antihemolytic factor, antibody, apolipoprotein, apoprotein, atrial natriuretic factor, atrial natriuretic polypeptide, atrial peptide, CXC chemokine, T39765, NAP-2, ENA-78, gro-a, gro-b, gro-c, IP-10, GCP-2, NAP-4, SDF-1, PF4, MIG, calcitonin, C-kit ligand, cytokine, CC chemokine, monocyte chemoattractant protein-1, monocyte chemoattractant protein 2, monocyte chemoattractant protein-3, monocyte inflammatory protein -1α, monocyte inflammatory protein-1β, RNATES, I309, R83915, R91733, HCC1, T58847, D31065, T64262, CD40, CD40 ligand, collagen, colony stimulating factor, complement factor 5a, complement inhibitor, complement receptor 1, cytokine, epithelial neutrophil activation peptide-78, MIP-16, MIP-1, epidermal growth factor, epithelial neutrophil activation peptide, erythropoietin, exfoliating toxin, factor IX, factor VII, factor VIII, factor X, fibroblast growth factor Factors, fibrinogen, fibronectin, four-helix bundle protein, G-CSF, glp-1, GM-CSF, glucocerebrosidase, gonadotropin, growth factor, growth factor receptor, hedgehog protein, hemoglobin, hepatocyte growth factor, hirudin, human growth hormone, human serum albumin, ICAM-1, ICAM-1 receptor, LFA-ULFA-1 receptor, insulin, insulin-like growth factor, IGFI, IGF-II, interferon, IFN-α, IFN-0.IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5, IL -6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, keratinocyte growth factor, lactoferrin, leukemia inhibitory factor, luciferase, nerve growth factor, neutrophil inhibitory factor, oncostatin M, osteogenic protein, oncogene products, paracitonin, parathyroid hormone, PD-ECSF, PDGF, peptide hormones, pleiotrophin, protein A, protein G, pth, pyrogenic exotoxin A, pyrogenic exotoxin B and pyrogenic exotoxin C, pyy, relaxin, renin, SCF, soluble complement receptor I, soluble I-CAM 1, soluble interleukin receptor, soluble TNF receptor, somatomedin, somatostatin, growth hormone, streptokinase, superantigen, staphylococcal enterotoxin, SEA.At least one of SEB, SECT, SEC2, SEC3, SED, SEE, steroid hormone receptor, superoxide dismutase, toxic shock syndrome toxin, thymosin α1, tissue plasminogen activator, tumor growth factor, tumor necrosis factor, tumor necrosis factor α, tumor necrosis factor β, tumor necrosis factor receptor, VLA-4 protein, VCAM-1 protein, vascular endothelial growth factor, urokinase, mos, ras, raf, met, p53, tat, fos, myc, jun, myb, rel, estrogen receptor, progesterone receptor, testosterone receptor, aldosterone receptor, LDL receptor, corticosterone, and fructose bisphosphate aldolase.
10. The recombinant protein according to claim 7, characterized in that The antibody or antibody fragment thereof includes at least one of a whole antibody, scFv, Fab, Fab', F(ab')2, scFv_Fc, Triabody, Diabody, Minibody, nanobody, DARPins or affibody.
